Effect of variants in COMT and UGT1A genes on clinical response in patients with Parkinson’s disease treated with opicapone
Objective: To identify genetic variants associated with different clinical responses in patients with Parkinson’s disease(PD) treated with opicapone. Background: Opicapone is a catechol‐O‐methyltransferase(COMT) inhibitor used…Adverse Events of Opicapone Adjunctive Therapy in 60 Consecutive Patients
Objective: This study aimed to investigate the risk of adverse events (AEs) when opicapone (OPC) was added as adjunctive therapy to L-dopa administration. Background: Levodopa…Opicapone versus entacapone: Head-to-head comparison of Healthcare Resource Utilisation in COMT-I naïve People with Parkinson’s
Objective: In this retrospective cohort study, we assessed healthcare resource utilisation (HCRU) outcomes in People with Parkinson’s (PwP) naïve to Catechol-O-methyl transferase (COMT) inhibition via…Levodopa-entacapone-carbidopa-infusion treatment in Parkinson’s disease: A six-month follow-up study
Objective: Objectives of this study were to evaluate changes in medication, adverse events and early discontinuations of levodopa-entacapone-carbidopa-intestinal-gel (LECIG) treatment in advanced Parkinson’s disease (PD).…Safety of opicapone after 5 years of post-marketing experience worldwide
Objective: To review the safety data of opicapone (OPC) after five years of marketing experience worldwide Background: OPC is a once-daily catechol-O-methyltransferase (COMT) inhibitor proven…Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson’s Disease Patients with Motor Fluctuations
Objective: This study aims to evaluate the effect of once-daily opicapone (OPC) 50 mg on the pharmacokinetics (PK) of levodopa (LD) in different LD/carbidopa (LD/CD)…Status Update of EPSILON: a Phase III, Randomised, Placebo-Controlled Study of Opicapone in Early Parkinson’s Disease
Objective: This study aims to explore the potential of once-daily opicapone (OPC) 50 mg to enhance the clinical benefit of levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi)…OCEAN Study in Parkinson’s Disease: Status Update of a Randomised Double-Blind Placebo-Controlled Trial of Opicapone
Objective: This study aims to evaluate if treatment with opicapone (OPC) 50 mg once-daily can improve motor fluctuation (MF)-related pain in patients with Parkinson’s disease…The REONPARK (REgistry of the use of COMT-inhibitors in the maNagement of patients with PARKinson’s disease in Spain who present early motor fluctuations) study: rationale and design of a national, multicentre and prospective study
Objective: To describe the real-world use of catechol-O-methyltransferase (COMT) inhibitors add on to levodopa/dopa decarboxylase inhibitor (DDCI) in patients with Parkinson’s disease (PD) suffering from…Early Morning Dystonia in Parkinson’s Patients Receiving Opicapone versus Entacapone: a Post-Hoc Analysis of BIPARK-I
Objective: This study evaluated the effect of once-daily opicapone (OPC) 50 mg versus entacapone (ENT) on Early Morning Dystonia (EMD) in Parkinson’s disease patients with…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »